A UK insurance group saved two point one million dollars on the OpenAI Enterprise framework through OpenAI Enterprise advisory framework, OpenAI ChatGPT Enterprise seat framework right sizing, and OpenAI commit framework optimization.
A UK insurance group came to us with a ChatGPT Enterprise renewal priced on 5,000 seats. Usage telemetry supported nowhere near that number. The renewal closed $2.1 million lower over the term.
This case study shows how seat truth, term design, and a credible alternative reshaped an OpenAI Enterprise negotiation.
The insurer cut $2.1 million from a ChatGPT Enterprise renewal by right sizing 5,000 provisioned seats to the population that actually used the product, then negotiating term and rate on the corrected base.
The original deployment came from a 2024 pilot that scaled fast on executive sponsorship. ChatGPT Enterprise seats were provisioned to whole departments, while sustained weekly usage concentrated in underwriting, claims, and a few hundred power users.
OpenAI proposed a flat renewal of all 5,000 seats with an uplift. Finance saw a number that had never been tested against usage. That test became the engagement.
Weekly active usage supported roughly 1,800 seats, not 5,000. About a third of provisioned users had not opened the product in 90 days, and another tranche used it less than monthly.
The admin console and SSO logs gave a defensible activity baseline. We classified users into daily, weekly, occasional, and dormant bands. Only daily and weekly bands justified Enterprise seats at renewal.
The agreement, governed by the OpenAI business terms, did not require maintaining the original seat count at renewal. Dormant seats were a commercial choice, not a contractual obligation. The enterprise privacy commitments were carried into the renewal unchanged.
Three levers moved the price: the corrected seat base, a twelve month term with growth options, and a live alternative evaluation running beside the negotiation.
Renewal positions. Opening vs closing
| Element | OpenAI opening | Closing position |
|---|---|---|
| Seats | 5,000 flat renewal | 1,900 committed, expansion options priced |
| Term | Three years | Twelve months with two renewal options |
| Rate | List with uplift | Negotiated rate below prior year effective |
| Occasional users | Enterprise seats | API based access for internal tools |
| Total term value | Baseline | $2.1 million lower |
A parallel evaluation of Anthropic Claude Enterprise and Microsoft 365 Copilot, scoped through API pricing comparisons for the internal tool workloads, gave the insurer a credible walk away story. Nothing disciplines a renewal like a tested alternative.
The closing sequence was telemetry, reclassification, alternative evaluation, then a single consolidated counterproposal. One counter, fully supported, beats a haggling sequence.
The common advice is to over provision AI seats because adoption is strategic and usage will catch up. We disagree. In roughly 20 to 30 GenAI negotiations we advised across 2024 and 2025, usage did not catch up to provisioning; provisioned seats ran 2x to 4x weekly active usage a year after rollout, and the surplus became the vendor’s renewal anchor. Strategic adoption is real, but it is served by expansion options priced in advance, not by paying for dormant seats. The buyer side move is to commit to measured usage, secure growth pricing in writing, and let the vendor carry the upside risk.
Source: Redress Compliance advisory engagement file, 2024 to 2025.
The renewal quote priced our ambition. The settlement priced our usage. Growth options covered the difference at no cost.
More GenAI buying analysis lives in the GenAI knowledge hub and our case study library.
The insurer saved $2.1 million over the renewal term. The saving came from reducing 5,000 provisioned seats to 1,900 committed seats, a below prior rate, and moving occasional workloads to API access.
Yes. ChatGPT Enterprise pricing is negotiated, not a published rate card. Seat volume, term length, timing, and a credible alternative all move the per seat number materially.
The defensible count is your weekly active user population plus a priced growth option. In our 2024 to 2025 engagements, provisioned seats ran 2x to 4x weekly active usage, which is pure renewal leverage for the vendor.
Generally no, not at current market velocity. GenAI pricing and packaging shifted within every twelve month window we tracked. Shorter terms with renewal options captured those drops; multi year locks paid 2024 prices in 2026.
API access is usually cheaper for occasional users and embedded tool workloads. A user who runs a few queries a week through an internal tool costs a fraction of a full seat at typical consumption rates.
We provisioned five thousand seats on enthusiasm. We renewed nineteen hundred on telemetry, with growth options if adoption proves the ambition right.
Confidential consultation. No follow up sales call unless you ask for one.
OpenAI Enterprise framework signals, Anthropic Claude framework signals, AI commit framework signals, and the broader generative AI licensing leverage signals across the practice.
Once a month. Audit patterns, renewal benchmarks, vendor commercial signals across Oracle, Microsoft, SAP, Salesforce, IBM, Broadcom, AWS, Google Cloud, ServiceNow, Workday, Cisco, and the GenAI vendors. No follow up sales pressure.
Free providers (Gmail, Yahoo, Outlook) cannot subscribe. Work email only. Unsubscribe in one click.
